CytoDyn Names Chris Recknor, M.D. Senior Executive VP of Clinical Operations to Initiate Two New Clinical Trials for Stroke and Alzheimer’s, While Nitya Ray, Ph.D. is Named CytoDyn’s New COO to Lead CMC and Regulatory Operations Specifically the BLA for HIV Oct 07, 2021 6:01am EDT
CytoDyn Announces Legal Actions Against its Former CRO, Amarex Clinical Research Oct 07, 2021 6:00am EDT
CytoDyn to Present at Emerging Growth Conference on September 29 Followed by Live Q/A Sep 27, 2021 12:30pm EDT
CytoDyn Receives Clearance from Brazil’s FDA (ANVISA) to Commence a Pivotal Phase 3 Trial in Critically Ill COVID-19 Patients with IV Administration of Four Doses (700mg/week) Sep 22, 2021 8:00am EDT
CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at the World Antiviral Congress 2021 Sep 21, 2021 8:00am EDT
CytoDyn Announces Resolution of Federal Litigation with Rosenbaum/Patterson Activist Group Sep 20, 2021 10:18am EDT
CytoDyn to Present at Emerging Growth Conference on September 15 Follow by Live Q/A Sep 13, 2021 6:00am EDT
CytoDyn Announces Treatment of the First Patient in its Pivotal Phase 3 COVID-19 Trial in Brazil for Patients with Severe Symptoms Sep 09, 2021 8:29pm EDT
CytoDyn to Hold Webcast on September 8 to Discuss Results from mTNBC Trials, HIV BLA Status, and Updates on COVID-19 and NASH Trials Sep 02, 2021 6:40pm EDT
